Literature DB >> 26673509

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.

Robert Hirten1, Randy S Longman2, Brian P Bosworth2, Adam Steinlauf2, Ellen Scherl2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26673509     DOI： 10.1038/ajg.2015.355

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  6 in total

1.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Authors:  Bruce E Sands; Richard Kozarek; Jack Spainhour; Charles F Barish; Scott Becker; Lawrence Goldberg; Seymour Katz; Ronald Goldblum; Rena Harrigan; Deborah Hilton; Stephen B Hanauer
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

2.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

3.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Authors:  Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245
  6 in total
  14 in total

1.  Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease.

Authors:  Clara Yzet; Jean-Louis Dupas; Mathurin Fumery
Journal:  Am J Gastroenterol       Date:  2016-05       Impact factor: 10.864

2.  Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis.

Authors:  Sarah Fischer; Timo Rath; Carol-Immanuel Geppert; Bernhard Manger; Georg Schett; Markus F Neurath; Raja Atreya
Journal:  Am J Gastroenterol       Date:  2017-10       Impact factor: 10.864

3.  Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Authors:  Claire Liefferinckx; Bram Verstockt; Ann Gils; Sophie Tops; Wouter Van Moerkercke; Severine Vermeire; Denis Franchimont
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

Review 4.  Update on Immune Checkpoint Inhibitor Enterocolitis.

Authors:  Molly R Kelly-Goss; Yousef R Badran; Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2022-10-20

Review 5.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 6.  Next-Generation Therapeutics for Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; William J Sandborn
Journal:  Curr Gastroenterol Rep       Date:  2016-09

7.  Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease.

Authors:  Eddie Y Liu; Dustin E Loomes
Journal:  Case Rep Med       Date:  2017-11-08

8.  A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.

Authors:  Dean Ehrlich; Nimah Jamaluddin; Joseph Pisegna; David Padua
Journal:  Case Rep Gastrointest Med       Date:  2018-02-15

9.  Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis.

Authors:  Johannes Bethge; Silvia Meffert; Mark Ellrichmann; Claudio Conrad; Susanna Nikolaus; Stefan Schreiber
Journal:  BMJ Open Gastroenterol       Date:  2017-02-08

Review 10.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.